Moderator: Renée JG Arnold, PharmD, RPh, Senior Principal, Global Health Economics, Icahn School of Medicine at Mount Sinai, Icon PLC, New York, NY, USA
Speakers: Nancy Risebrough, BA, Principal, Global HTA, Health Economics, Reimbursement and Outcomes, ICON plc, Toronto, ON, Canada; Jeroen P Jansen, PhD, Senior Director of Biostatistics, Innovation and Value Initiative, Los Angeles, CA, USA; Lotte Steuten, PhD, MSc, Vice-President, Head of Consulting, The Office of Health Economics, London, UK; Gian Luca Di Tanna, PhD, Senior Manager, Global Health Economics, Economic Modeling CoE, Global Health Economics, Amgen (Europe) GmbH, Zug, Switzerland

Cost-effectiveness and disease models are often statistically sophisticated and may be seen as opaque by stakeholders [1]. Open-source models (OSM) would encourage greater transparency and facilitate the reuse and updating of the best/most useful models. Per ISPOR-SMDM and EUnetHTA, OSM will advance modeling methods by reducing bias, increasing transparency, improving model access, and allowing for faster access to critical knowledge. With openness and sharing come issues of copyright and access and a need to define how model sharing can be achieved in an equitable manner. The pros and cons of OSMs and the proposed mission of the Open Source Model SIG will be debated amongst SIG members.

1. Follow on to Issue Panel (ISPOR 2018, Baltimore, MD), chaired by Neil Hawkins, MD, with Renée Arnold, PharmD and Jaime Caro, MD as panelists, entitled Lies, Damned Lies and Cost-Effectiveness: Open-Source Models are Essential if Cost-Effectiveness Analyses are to be Widely Accepted.